Role of Natural Killer Cell Diversity in Multiple Sclerosis Risk and Disease Course
自然杀伤细胞多样性在多发性硬化症风险和疾病过程中的作用
基本信息
- 批准号:10707310
- 负责人:
- 金额:$ 76.08万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-09-19 至 2027-07-31
- 项目状态:未结题
- 来源:
- 关键词:African AmericanAllelesBiological AssayCRISPR interferenceCRISPR-mediated transcriptional activationCRISPR/Cas technologyCell TherapyCell physiologyCellular biologyChromosome 12Chromosome 19ClinicalComplexCytometryDataDimensionsDiseaseDisease ProgressionDisease remissionEuropean ancestryFutureGenomic SegmentGenomicsGenotypeGoalsHispanic ancestryImmunoglobulinsIn VitroIndividualInvestigationKiller CellsLeukocytesLigandsLongitudinal cohortMagnetic Resonance ImagingMapsMediatingMethodologyMethodsModalityMultiple SclerosisNatural Killer CellsNaturePathogenesisPatternPhenotypePredispositionReceptor CellRelapseResolutionRiskRoleSurfaceSystemTechnologyTest ResultTherapeuticVariantWorkclinical applicationcohortcytotoxicityexperimental studygenomic datagenomic variationinducible gene expressioninsightknock-downmultiple sclerosis patientnext generation sequencingnovelpatient populationperipheral bloodphenotypic datareceptorreceptor expression
项目摘要
Project Summary
The goal of this project is to comprehensively characterize the role of polymorphic natural killer (NK) cell
receptors in multiple sclerosis (MS). Substantial data implicate NK cells in MS pathogenesis, but their precise
function in mediating risk and disease course is poorly understood. Given that a large and diverse set of highly
variable receptors govern NK cell activity, their characterization in MS promises to yield important insights into
the role of NK cells in disease. Thus, we will characterize the nature and extent of the association of genomic
variation of NK receptors across a set of diverse, established and deeply phenotyped MS cohorts. This goal will
be achieved via our novel high-throughput, high-resolution next-generation sequencing (NGS) methodology.
Using state-of-art technologies, we will contextualize this genomic variation by considering NK cell phenotype in
disease. Finally, we will explore the functional implications of the observed NK receptor variation, allowing a
mechanistic explanation of the impact of NK receptor expression to more fully understand the role of these highly
variable receptors in MS. Together, the leukocyte receptor complex (LRC) on chromosome 19 and the natural
killer complex (NKC) on chromosome 12 encode more than 90 distinct NK cell receptors, including the extremely
polymorphic KIR (killer-cell immunoglobulin-like receptor) and LILR (leukocyte immunoglobulin-like receptors).
In the work described here, we approach these complex systems across several key modalities, examining
genomic, phenotypic and functional variation of NK receptors in MS to provide the first comprehensive depiction
of the role of NK receptors in disease. Our preliminary work in a cohort of European ancestry identified a
significant association of KIR variation with risk for developing MS, as well as with clinical and MRI features of
disease. In Specific Aim 1, we will extend these findings to diverse patient populations and characterize KIR
variation in MS across ancestries, in an additional cohort with longitudinal clinical and MRI data, and by
investigating genomic variation of all known polymorphic NK receptors and their corresponding ligands. In
Specific Aim 2, we will more fully resolve the role of these receptors in disease course by examining temporal
expression patterns of NK cell receptors in individuals with MS through longitudinal CyTOF analysis. Finally, in
Specific Aim 3, we will contextualize these results by harnessing CRISPR technology to characterize the impact
of NK cell receptor expression level on NK cell function. This work promises to fill critical gaps in our
understanding of the role of NK cells in MS. Because NK cell activity is tightly governed by the highly variable
receptors that we investigate in this proposal, this work will provide important insight into the regulatory
mechanisms underlying the influence of NK cells in MS susceptibility and disease course. The results will bear
both on our understanding of disease pathogenesis and future efforts to develop NK cell-based therapeutic
options.
项目摘要
本项目的目标是全面表征多态性自然杀伤(NK)细胞的作用,
多发性硬化症(MS)中的受体。大量数据表明NK细胞参与MS发病机制,但其精确的
在介导风险和疾病过程中的功能知之甚少。鉴于一个庞大而多样化的高度
可变受体控制NK细胞活性,它们在MS中的特征有望产生重要的见解,
NK细胞在疾病中的作用因此,我们将描述基因组关联的性质和程度,
NK受体在一组不同的、已建立的和深度表型化的MS队列中的变异。这一目标将
通过我们新颖的高通量、高分辨率的下一代测序(NGS)方法实现。
使用最先进的技术,我们将通过考虑NK细胞表型来了解这种基因组变异,
疾病最后,我们将探讨观察到的NK受体变异的功能意义,
机制解释NK受体表达的影响,以更充分地了解这些高度
总之,19号染色体上的白细胞受体复合物(LRC)和MS中的天然白细胞受体复合物(LRC)。
12号染色体上的杀伤复合物(NKC)编码90多种不同的NK细胞受体,包括极端的
多态性KIR(白细胞免疫球蛋白样受体)和LILR(白细胞免疫球蛋白样受体)。
在这里描述的工作中,我们通过几种关键模式来处理这些复杂的系统,
MS中NK受体的基因组、表型和功能变异,以提供第一个全面的描述
NK受体在疾病中的作用。我们在一个欧洲血统队列中的初步工作确定了一个
KIR变异与MS发生风险以及MS的临床和MRI特征显著相关,
疾病在具体目标1中,我们将把这些发现扩展到不同的患者人群,并描述KIR的特征。
在具有纵向临床和MRI数据的额外队列中,
研究所有已知的多态性NK受体及其相应配体的基因组变异。在
具体目标2,我们将更充分地解决这些受体在疾病过程中的作用,通过检查时间
通过纵向CyTOF分析MS个体中NK细胞受体的表达模式。最后在
具体目标3,我们将通过利用CRISPR技术来描述这些结果的影响,
NK细胞受体表达水平对NK细胞功能的影响。这项工作有望填补我们的关键空白,
由于NK细胞活性受到高度可变的
受体,我们在这项建议中调查,这项工作将提供重要的洞察力的调节
NK细胞在MS易感性和疾病过程中的影响机制。结果将承担
无论是我们对疾病发病机制的理解,还是未来开发基于NK细胞的治疗药物的努力,
选项.
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JILL Allison HOLLENBACH其他文献
JILL Allison HOLLENBACH的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JILL Allison HOLLENBACH', 18)}}的其他基金
Role of Natural Killer Cell Diversity in Multiple Sclerosis Risk and Disease Course
自然杀伤细胞多样性在多发性硬化症风险和疾病过程中的作用
- 批准号:
10586853 - 财政年份:2022
- 资助金额:
$ 76.08万 - 项目类别:
The landscape of HLA mediated variation in health and immunity
HLA 介导的健康和免疫力变化
- 批准号:
10182837 - 财政年份:2021
- 资助金额:
$ 76.08万 - 项目类别:
MHC Variation in Host Response to SARS-CoV2 and COVID-19 Outcomes
宿主对 SARS-CoV2 和 COVID-19 结果反应的 MHC 变化
- 批准号:
10655366 - 财政年份:2021
- 资助金额:
$ 76.08万 - 项目类别:
MHC Variation in Host Response to SARS-CoV2 and COVID-19 Outcomes
宿主对 SARS-CoV2 和 COVID-19 结果反应的 MHC 变化
- 批准号:
10450114 - 财政年份:2021
- 资助金额:
$ 76.08万 - 项目类别:
The landscape of HLA mediated variation in health and immunity
HLA 介导的健康和免疫力变化
- 批准号:
10402884 - 财政年份:2021
- 资助金额:
$ 76.08万 - 项目类别:
MHC Variation in Host Response to SARS-CoV2 and COVID-19 Outcomes
宿主对 SARS-CoV2 和 COVID-19 结果反应的 MHC 变化
- 批准号:
10297642 - 财政年份:2021
- 资助金额:
$ 76.08万 - 项目类别:
The landscape of HLA mediated variation in health and immunity
HLA 介导的健康和免疫力变化
- 批准号:
10609519 - 财政年份:2021
- 资助金额:
$ 76.08万 - 项目类别:
Integrated Exchange and Storage of Current- and Future-Generation Immunogenomic Data
当前和未来一代免疫基因组数据的集成交换和存储
- 批准号:
10442226 - 财政年份:2017
- 资助金额:
$ 76.08万 - 项目类别:
Integrated Exchange and Storage of Current- and Future-Generation Immunogenomic Data
当前和未来一代免疫基因组数据的集成交换和存储
- 批准号:
10553161 - 财政年份:2017
- 资助金额:
$ 76.08万 - 项目类别:
MHC variation at high resolution in multiple sclerosis
多发性硬化症中 MHC 高分辨率变异
- 批准号:
9353595 - 财政年份:2017
- 资助金额:
$ 76.08万 - 项目类别:
相似海外基金
Linkage of HIV amino acid variants to protective host alleles at CHD1L and HLA class I loci in an African population
非洲人群中 HIV 氨基酸变异与 CHD1L 和 HLA I 类基因座的保护性宿主等位基因的关联
- 批准号:
502556 - 财政年份:2024
- 资助金额:
$ 76.08万 - 项目类别:
Olfactory Epithelium Responses to Human APOE Alleles
嗅觉上皮对人类 APOE 等位基因的反应
- 批准号:
10659303 - 财政年份:2023
- 资助金额:
$ 76.08万 - 项目类别:
Deeply analyzing MHC class I-restricted peptide presentation mechanistics across alleles, pathways, and disease coupled with TCR discovery/characterization
深入分析跨等位基因、通路和疾病的 MHC I 类限制性肽呈递机制以及 TCR 发现/表征
- 批准号:
10674405 - 财政年份:2023
- 资助金额:
$ 76.08万 - 项目类别:
An off-the-shelf tumor cell vaccine with HLA-matching alleles for the personalized treatment of advanced solid tumors
具有 HLA 匹配等位基因的现成肿瘤细胞疫苗,用于晚期实体瘤的个性化治疗
- 批准号:
10758772 - 财政年份:2023
- 资助金额:
$ 76.08万 - 项目类别:
Identifying genetic variants that modify the effect size of ApoE alleles on late-onset Alzheimer's disease risk
识别改变 ApoE 等位基因对迟发性阿尔茨海默病风险影响大小的遗传变异
- 批准号:
10676499 - 财政年份:2023
- 资助金额:
$ 76.08万 - 项目类别:
New statistical approaches to mapping the functional impact of HLA alleles in multimodal complex disease datasets
绘制多模式复杂疾病数据集中 HLA 等位基因功能影响的新统计方法
- 批准号:
2748611 - 财政年份:2022
- 资助金额:
$ 76.08万 - 项目类别:
Studentship
Recessive lethal alleles linked to seed abortion and their effect on fruit development in blueberries
与种子败育相关的隐性致死等位基因及其对蓝莓果实发育的影响
- 批准号:
22K05630 - 财政年份:2022
- 资助金额:
$ 76.08万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Genome and epigenome editing of induced pluripotent stem cells for investigating osteoarthritis risk alleles
诱导多能干细胞的基因组和表观基因组编辑用于研究骨关节炎风险等位基因
- 批准号:
10532032 - 财政年份:2022
- 资助金额:
$ 76.08万 - 项目类别:
Investigating the Effect of APOE Alleles on Neuro-Immunity of Human Brain Borders in Normal Aging and Alzheimer's Disease Using Single-Cell Multi-Omics and In Vitro Organoids
使用单细胞多组学和体外类器官研究 APOE 等位基因对正常衰老和阿尔茨海默病中人脑边界神经免疫的影响
- 批准号:
10525070 - 财政年份:2022
- 资助金额:
$ 76.08万 - 项目类别:
Leveraging the Evolutionary History to Improve Identification of Trait-Associated Alleles and Risk Stratification Models in Native Hawaiians
利用进化历史来改进夏威夷原住民性状相关等位基因的识别和风险分层模型
- 批准号:
10689017 - 财政年份:2022
- 资助金额:
$ 76.08万 - 项目类别: